Clinical Trials | December 20, 2022
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The product is backed by required scientific proof and comparative bioequivalence studies
Post the sale, Patel family has become the single largest promoter shareholder in the company
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated
